Doximity (DOCS) Stock Forecast & Price Target

Doximity Inc has demonstrated robust financial performance, with FY3Q26 revenues rising 10% year-over-year to $185.1 million, surpassing both guidance and consensus estimates. The company has reported strong demand from existing customers, particularly its top 20 clients, leading to a 10% year-over-year increase in the number of clients spending over $500,000 annually. Additionally, Doximity's user engagement metrics reached new records, reflecting a solid foundation for continued growth and a promising trajectory in the digital healthcare advertising sector.

Doximity Inc. has reported a decline in gross margins, falling to 91.5% from 91.9% in the previous quarter and from 93.3% year-over-year, indicating potential pressure on profitability. The company's outlook for FYQ4 FY2026 reflects only approximately 4% year-over-year growth, primarily attributed to industry-wide policy headwinds impacting pharmaceutical clients' budgeting. Additionally, the net revenue retention (NRR) rate for the top 20 customers has decreased to 112%, down from 118% last quarter and 117% year-over-year, signaling weakening performance in customer retention and growth potential.